RNS Number : 9139B Renalytix AI PLC 15 June 2021 Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 NEW YORK , June 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("Renalytix" or the "Company") today reported financial results for the quarter and nine months
Announces Change of Auditor to Ernst & Young LLP NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open.
RNS Number : 4033B Renalytix AI PLC 10 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update Announces Change of Auditor to Ernst & Young LLP NEW YORK , June 10, 2021 - Renalytix AI
Enabling expertise in sales, population health and value-driven care models NEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United States market in light
RNS Number : 9511A Renalytix AI PLC 07 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment Enabling expertise in sales, population health and value-driven care models
Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study.
RNS Number : 6483A Renalytix AI PLC 03 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment
RNS Number : 7052Z Renalytix AI PLC 25 May 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing New York , 25 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 10,462
RNS Number : 4140Z Renalytix AI PLC 21 May 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing New York , 21 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 54,538
Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management NEW YORK and CHARLOTTE, N.C. and WINSTON-SALEM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE:
